Showing results (41-50 of 107) with videos related to

Sort By:
Pageof 11
Cancer|March 19, 2008
Survival and predictors of outcome in patients with acute leukemia admitted to the intensive care unitSnehal G Thakkar, Alex Z Fu, John W Sweetenham, et al.
The Oncologist|April 29, 2023
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic SyndromesSudipto Mukherjee, Weichuan Dong, Nicholas K Schiltz, et al.
American Journal of Hematology|June 26, 2012
Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemiaDi Sun, Paul Elson, Michaela Liedtke, et al.
Cancer|March 29, 2019
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE studyHagop M Kantarjian, Daniel J DeAngelo, Matthias Stelljes, et al.
Blood Cancer Journal|August 10, 2020
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burdenDaniel J DeAngelo, Anjali S Advani, David I Marks, et al.
Cancer|January 31, 2018
Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATEElias J Jabbour, Daniel J DeAngelo, Matthias Stelljes, et al.
American Journal of Hematology|July 6, 2013
Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weightCandice M Wenzell, Erika M Gallagher, Marc Earl, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 1, 2019
Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic LeukemiaDavid I Marks, Partow Kebriaei, Matthias Stelljes, et al.
The New England Journal of Medicine|June 14, 2016
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic LeukemiaHagop M Kantarjian, Daniel J DeAngelo, Matthias Stelljes, et al.
Blood|September 20, 2021
Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemiaDaniel J DeAngelo, Brian A Jonas, Jane L Liesveld, et al.
Pageof 11